drugset / Trial / NCT00139347

Study of 2 Doses of HRV Vaccine Given Concomitantly With Routine EPI Vaccinations Including OPV in Healthy Infants

NCT00139347 ↗

Phase 3 Completed 6360 enrolled GlaxoSmithKline
RandomizedParallel-groupDouble-blindPrevention

Summary

The main objectives of this study is to determine vaccine efficacy against severe rotavirus (RV) gastroenteritis (GE) during the period starting from 2 weeks after Dose 2 until one year of age.

Timeline

Start
2003-12
Primary completion
2007-03
Completion
2007-03

Outcome

Met primary endpoint

paper The efficacy of the vaccine against severe rotavirus gastroenteritis and against rotavirus-associated hospitalization was 85 percent (P<0.001 for the comparison with placebo) PMID 16394298 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject G1P[8] human rotavirus vaccine Vaccine — Oral

Indications